The genomic landscape of hypodiploid acute lymphoblastic leukemia

Nature Genetics

Volumn 45, Issue 3, 2013, Pages 242-252

  Holmfeldt, Linda ^a   Wei, Lei ^a   Diaz Flores, Ernesto ^b   Walsh, Michael ^a   Zhang, Jinghui ^a   Ding, Li ^c   Payne Turner, Debbie ^a   Churchman, Michelle ^a   Andersson, Anna ^a,d   Chen, Shann Ching ^a   Mccastlain, Kelly ^a   Becksfort, Jared ^a   Ma, Jing ^a   Wu, Gang ^a   Patel, Samir N ^a   Heatley, Susan L ^a   Phillips, Letha A ^a   Song, Guangchun ^a   Easton, John ^a   Parker, Matthew ^a   Chen, Xiang ^a   Rusch, Michael ^a   Boggs, Kristy ^a   Vadodaria, Bhavin ^a   Hedlund, Erin ^a   Drenberg, Christina ^a   Baker, Sharyn ^a   Pei, Deqing ^a   Cheng, Cheng ^a   Huether, Robert ^a   Lu, Charles ^c   Fulton, Robert S ^c   Fulton, Lucinda L ^c   Tabib, Yashodhan ^c   Dooling, David J ^c   Ochoa, Kerri ^c   Minden, Mark ^e   Lewis, Ian D ^f   To, L Bik ^f   Marlton, Paula ^g   Roberts, Andrew W ^h   Raca, Gordana ⁱ   Stock, Wendy ⁱ   Neale, Geoffrey ^a   Drexler, Hans G ^j   Dickins, Ross A ^k   Ellison, David W ^a   Shurtleff, Sheila A ^a   Pui, Ching Hon ^a   Ribeiro, Raul C ^a   Devidas, Meenakshi ^l   Carroll, Andrew J ^m   Heerema, Nyla A ⁿ   Wood, Brent ^o   Borowitz, Michael J ^p   Gastier Foster, Julie M ^q,r   Raimondi, Susana C ^a   Mardis, Elaine R ^a,c,s   Wilson, Richard K ^a,c,s   Downing, James R ^a   Hunger, Stephen P ^t   Loh, Mignon L ^b   Mullighan, Charles G ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j University of Chicago Medicine ^*  (Germany)

^k WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^l UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ OHIO STATE UNIVERSITY   (United States)

^o SEATTLE CHILDREN S HOSPITAL   (United States)

^p JOHNS HOPKINS HOSPITAL   (United States)

^q NATIONWIDE CHILDREN S HOSPITAL   (United States)

^r OHIO STATE UNIVERSITY   (United States)

^s USA   (United States)

^t UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; PROTEIN TYROSINE KINASE; RAS PROTEIN; TRANSCRIPTION FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEUPLOIDY; ARTICLE; CHILD; CHROMOSOME; DISEASE SEVERITY; EXOME; EXON; GENE; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; HAPLOIDY; HUMAN; HYPODIPLOID ACUTE LYMPHOBLASTIC LEUKEMIA; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANEUPLOIDY; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOIDY; HUMANS; IKAROS TRANSCRIPTION FACTOR; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874647204     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2532     Document Type: Article

References (85)

1. Pui, CH. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730-2741 (2009
2. Kuiper, RP. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21, 1258-1266 (2007
3. Mullighan, CG. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007
4. Kuiper, RP. et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 24, 1258-1264 (2010
5. Mullighan, CG. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470-480 (2009
6. Mullighan, CG. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235-239 (2011
7. Harrison, CJ. et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br. J. Haematol. 125, 552-559 (2004
8. Heerema, NA. et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the children's cancer group. Blood 94, 4036-4045 (1999
9. Nachman, JB. et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110, 1112-1115 (2007
10. Raimondi, SC. et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98, 2715-2722 (2003
11. Raimondi, SC. Cytogenetics of acute leukemias. in Childhood Leukemias (ed. Pui, CH.) (Cambridge University Press, 2012
12. Carroll, AJ. et al. Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL). in Children mimicking hyperdiploid ALL: A report from the Children's Oncology Group (COG) AALL03B1 study. Blood: ASH Annual Meeting Abstracts 114, 1580 (2009
13. Li, FP. & Fraumeni, JF. Jr. Soft-Tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747-752 (1969
14. Malkin, D. Li-Fraumeni syndrome. Genes Cancer 2, 475-484 (2011
15. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012
16. Xu, GF. et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62, 599-608 (1990
17. Cawthon, RM. et al. A major segment of the neurofibromatosis type 1 gene: CDNA sequence, genomic structure, and point mutations. Cell 62, 193-201 (1990
18. Viskochil, D. et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187-192 (1990
19. Wallace, MR. et al. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science 249, 181-186 (1990
20. Side, LE. et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92, 267-272 (1998
21. Balgobind, BV. et al. Leukemia-Associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 111, 4322-4328 (2008
22. McLendon, R. et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008
23. Klopfenstein, KJ., Sommer, A. & Ruymann, FB. Neurofibromatosis-Noonan syndrome and acute lymphoblastic leukemia: A report of two cases. J. Pediatr. Hematol. Oncol. 21, 158-160 (1999
24. Stiller, CA., Chessells, JM. & Fitchett, M. Neurofibromatosis and childhood leukaemia/lymphoma: A population-based UKCCSG study. Br. J. Cancer 70, 969-972 (1994
25. Messiaen, L. et al. Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum. Mutat. 32, 213-219 (2011
26. Marculescu, R. et al. Recombinase, chromosomal translocations and lymphoid neoplasia: Targeting mistakes and repair failures. DNA Repair (Amst.) 5, 1246-1258 (2006
27. Mullighan, CG. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110-114 (2008
28. Kohno, S., Minowada, J. & Sandberg, AA. Chromosome evolution of near-haploid clones in an established human acute lymphoblastic leukemia cell line (NALM-16). J. Natl. Cancer Inst. 64, 485-493 (1980
29. Kratz, CP. et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106, 2183-2185 (2005
30. Tartaglia, M. et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78, 279-290 (2006
31. De Filippi, P. et al. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br. J. Haematol. 147, 706-709 (2009
32. Matsuda, K. et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 109, 5477-5480 (2007
33. Kawabuchi, M. et al. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404, 999-1003 (2000
34. Brdicka, T. et al. Phosphoprotein associated with glycosphingolipid- enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J. Exp. Med. 191, 1591-1604 (2000
35. Davidson, D., Bakinowski, M., Thomas, ML., Horejsi, V. & Veillette, A. Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-Associated transmembrane adaptor. Mol. Cell. Biol. 23, 2017-2028 (2003
36. Zhang, SQ. et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 13, 341-355 (2004
37. Kalland, ME., Solheim, SA., Skanland, SS., Tasken, K. & Berge, T. Modulation of proximal signaling in normal and transformed B cells by transmembrane adapter Cbp/PAG. Exp. Cell Res. 318, 1611-1619 (2012
38. Imamura, J., Miyoshi, I. & Koeffler, HP. p53 in hematologic malignancies. Blood 84, 2412-2421 (1994
39. Zhang, J. et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 118, 3080-3087 (2011
40. Petitjean, A. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum. Mutat. 6, 622-629 (2007
41. Cho, Y., Gorina, S., Jeffrey, PD. & Pavletich, NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355 (1994
42. Hof, J. et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 29, 3185-93 (2011
43. Wattel, E. et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148-3157 (1994
44. Rovinski, B. & Benchimol, S. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2, 445-452 (1988
45. el-Deiry, WS. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993
46. Rebollo, A. & Schmitt, C. Ikaros, Aiolos and Helios: Transcription regulators and lymphoid malignancies. Immunol. Cell Biol. 81, 171-175 (2003
47. Georgopoulos, K. et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79, 143-156 (1994
48. Wang, JH. et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537-549 (1996
49. Kim, J. et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 10, 345-355 (1999
50. Thornton, AM. et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184, 3433-3441 (2010
51. Getnet, D. et al. A role for the transcription factor Helios in human CD4+CD25+ regulatory T cells. Mol. Immunol. 47, 1595-1600 (2010
52. Sugimoto, N. et al. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int. Immunol. 18, 1197-1209 (2006
53. Hahm, K. et al. Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. Genes Dev. 12, 782-796 (1998
54. Kelley, CM. et al. Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. Curr. Bio. 8, 508-15 (1998
55. Goodman, RH. & Smolik, S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553-1577 (2000
56. Kasper, LH. et al. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J. 24, 3846-3858 (2005
57. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011
58. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010
59. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, CC. p53 mutations in human cancers. Science 253, 49-53 (1991
60. Lohmann, D. Retinoblastoma. Adv. Exp. Med. Biol. 685, 220-227 (2010
61. Stephens, PJ. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011
62. Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59-71 (2012
63. Hanel, W. & Moll, UM. Links between mutant p53 and genomic instability. J. Cell. Biochem. 113, 433-439 (2012
64. Li, M. et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc. Natl. Acad. Sci. USA 107, 14188-14193 (2010
65. Thompson, SL. & Compton, DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J. Cell Biol. 188, 369-381 (2010
66. Deshpande, A. & Hinds, PW. The retinoblastoma protein in osteoblast differentiation and osteosarcoma. Curr. Mol. Med. 6, 809-817 (2006
67. Romero, F., Martinez, AC., Camonis, J. & Rebollo, A. Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization. EMBO J. 18, 3419-3430 (1999
68. Krzywinski, M. et al. Circos: An information aesthetic for comparative genomics. Genome Res. 19, 1639-1645 (2009
69. Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011
70. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010
71. Mardis, ER. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009
72. Downing, JR. et al. The Pediatric Cancer Genome Project. Nat. Genet. 44, 619-622 (2012
73. Sherry, ST. et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001
74. Lin, M. et al. dChipSNP: Significance curve and clustering of SNP-Array-based loss-of-heterozygosity data. Bioinformatics 20, 1233-1240 (2004
75. Venkatraman, ES. & Olshen, AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657-663 (2007
76. Rozen, S. & Skaletsky, HJ. Bioinformatics Methods and Protocols (Methods in Molecular Biology). (Humana Press, 2000
77. Zhang, J. et al. SNPdetector: A software tool for sensitive and accurate SNP detection. PLOS Comput. Biol. 1, e53 (2005
78. Chen, K. et al. PolyScan: An automatic indel and SNP detection approach to the analysis of human resequencing data. Genome Res. 17, 659-666 (2007
79. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
80. Donovan, S., See, W., Bonifas, J., Stokoe, D. & Shannon, KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2, 507-514 (2002
81. Schubbert, S. et al. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38, 331-336 (2006
82. Peto, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br. J. Cancer 35, 1-39 (1977
83. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50, 163-170 (1966
84. Fine, JP. & Gray, RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496-509 (1999
85. R Development Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, 2006